PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer

Laura H. Porter; Mitchell G. Lawrence; Nicholas Choo; Shahneen Sandhu; Hong Wang; David Pook; Elaine Sanij; Richard B. Pearson; Ross D. Hannan; Luc Furic; Renea A. Taylor; Gail P. Risbridger

doi:10.1530/oncolabs.1.p042

Related publications

Article2019

New combination therapies for castration-resistant prostate cancer

Mitchell G. Lawrence, Laura H. Porter, Daisuke Obinata, Shahneen Sandhu, Luke A. Selth, Stephen Q. Wong, Nicholas Choo, David Pook, Carmel Pezaro, David L. Goode, Ashlee K. Clark, Melissa Papargiris, Roxanne Toivanen, Scott M. Dehm, Scott M CASCADE, Scott M kConfab, Heather Thorne, Wayne D. Tilley, Richard B. Pearson, Ross D. Hannan, Declan G. Murphy, Mark Frydenberg, Luc Furic, Renea A. Taylor, Gail P. Risbridger

Article2024

Appraisal of modified tests for the diagnosis and treatment of primary aldosteronism: A single endocrine center experience

Αthina Markou, Gregory Kaltsas, Labrini Papanastasiou, Nikolaos Voulgaris, Aggeliki Gouli, Vaios Tsiavos, Christos Gravvanis, Ernestini Tyfoxylou, Sofia Vlachou, Chara Kapsali, Irini Giagourta, Theodora Kounadi, Kyriakos Vamvakidis, George Zografos, George Chrousos, George Piaditis

Article2015

PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer

Abstract

Discussion(0)

Related publications

New combination therapies for castration-resistant prostate cancer

Appraisal of modified tests for the diagnosis and treatment of primary aldosteronism: A single endocrine center experience

Thalassemia-induced osteoporosis and bisphosphonate treatment: a systematic review and meta-analysis

A Novel CDKN1B mutation in multiple endocrine neoplasia type 4

Thyroid hormone treatment counteracts pathological alterations in diabetic nephropathy and diabetic cardiomyopathy